Through acquisitions and strong organic growth, Valeant Europe has expanded its presence throughout Europe and the Middle East, generating revenues in more than 30 countries from. Our products are sold primarily in Poland, Russia, France and Germany.
In Western Europe we have significantly strengthened our presence in niche markets, specifically eye health, as a result of our 2013 acquisition of Bausch + Lomb, positioning Valeant to capitalize on growing eye health trends driven by an aging patient population and demand from emerging markets. The largest products in Western Europe are Artelac, eye drops for treatment of dry eye, and Purevision, monthly contact lenses.
Our strategy in Central and Eastern Europe is to develop and commercialize modern, high added-value generics and OTC products which represent a quality, affordable alternative to brand name counterparts. Our branded generic products are sold largely under the Valeant umbrella brand; however, in countries where the brand names of legacy companies still resonate with healthcare professionals and consumers, we have chosen (for certain products) to retain on our packaging the logos of some of the historical companies that make up Valeant Europe — ICN Polfa (specifically Poland), PharmaSwiss (specifically Serbia) and Sanitas (specifically Poland and Lithuania).
Our combined branded generics business now covers a broad range of treatments including antibiotics, treatments for cardiovascular and neurological diseases, antifungal medications and diabetic therapies. In Poland, our largest product is Bisocard®, a beta-blocker that is indicated to treat hypertension and angina pectoris.
Eye health also plays a significant role within the Middle East and Turkey, where we offer a broad range of contact lenses and lens solutions, pharmaceuticals, surgical equipment and intraocular lenses.